Danish drugmaker Novo Nordisk announced its plans to cut the prices of insulin in the U.S. amid rising criticism over the treatment’s high prices, Reuters reports.
According to the report, the drugmaker will offer a generic version of Novolog, an insulin drug used by roughly one million patients in the U.S., at a 50 percent discount. One vial will carry a $144.68 price tag.
“While we will continue to do what we can to help address affordability challenges in the short-term, changes within the system are required to make sustainable and meaningful affordability a reality,” Novo Nordisk said in a statement.
To read the full report on Reuters, click here.